Company Reports / Boehringer Ingelheim
COMPANY: Boehringer Ingelheim
INDEX RANK: 10th
Total Impact Score: 336,061.67
Boehringer Ingelheim is ranked 10th place in our index for 2015. Boehringer Ingelheim’s drugs have a total impact score of 336,061.67. Boehringer Ingelheim treats one disease in our model - HIV - with one total drug - Nevirapine (NVP). Boehringer Ingelheim receives credit for one treatment against HIV - Nevirapine (NVP). This one drug averted 326,973.41 of the total DALYS for HIV, which is 12.76% of the worldwide DALYs that we estimate would have been lost due to HIV in 2015 in the absence of effective treatment. Boehringer Ingelheim’s drug portfolio placed it 5th in terms of total averted DALYs for HIV.
Company Score Breakdown:
Nevirapine (NVP) is an ARV drug recommended by the WHO in the treatment of HIV as a part of alternative first and second-line regimens for adults, adolescents, and children. Major toxicity concerns include hepatotoxicity and hypersensitivity reactions. NVP was first patented by Boehringer Ingelheim.
Boehringer Ingelheim is a global pharmaceutical company headquartered in Ingelheim, Germany, founded in 1885 by Albert Boehringer. BI manufactures and researches medicines for humans as well as animals. BI works to improve access to essential medicine by collaborating with the Medicine Patent Pool to waive patent rights to needed medicines, using tiered pricing schemes, and donating anti-retroviral drugs to increase access to HIV medication, such as Viramune®. They recently began an Access to Healthcare Strategy looking to improve access to essential medicines in low and middle income countries, primarily focusing on noncommunicable diseases such as diabetes and obesity. Major products include Aggrenox®, Flomax®, and Viramune®. The company operates in over 100 countries with about 50,000 employees, earning a revenue of $20.8 billion in 2017.